The number of new I/O cancer drugs in the clinic continues to swell at an explosive pace -- offering new hope, fresh concerns

The juggernaut of immuno-oncology drug research around the world continues to rapidly gain speed and mass, offering patients with virtually every cancer type the prospect of new combinations or monotherapies that may bend the course of their disease, according to a new study mapping the global landscape of I/O. But it also raises fresh concerns about commoditization and patient recruitment as the number of PD-1/L1s on the market continues to multiply, with hundreds more coming from behind in the pipeline.